The Body Covers: The 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy Coverage
The 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy
September 15, 2000
Lisa Ware from the Chelsea and Westminster hospital in London looked at the rate of clearance of labeled triacylglycerol (TAG) and non-esterified fatty acids (NEFA) in a cohort of patients on protease inhibitor-based therapy who were experiencing lipodystrophy. She compared these patients to patients in double nucleoside regimens who also had lipodystrophy. Patients on protease inhibitors with lipodystrophy had an increased retention time of lipids as TAG vs. the other group that tended to retain as NEFA. This suggests that things are never simple and that these differences may influence the evolution of body composition in different antiretroviral regimens.
Colleen Hadigan from the Harvard group presented data demonstrating that the levels of tissue plasminogen activator (tPA) -- a marker of increased cardiovascular risk -- were increased in patients with lipodystrophy, when compared to the Framingham cohort. These levels decreased after treatment with metformin, which could improve the cardiovascular risk of these patients.
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.